- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Neurofibromatosis type 1
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 900KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 202KB)
Selumetinib – March 2024
Selumetinib: Capsule 10 mg, Capsule 25 mg; Koselugo®
Last updated
30 May 2025